Affimed N.V (NASDAQ: AFMD) has experienced a rise in its stock price by 10.55 compared to its previous closing price of 1.00. However, the company has seen a gain of 23.60% in its stock price over the last five trading days. https://www.marketscreener.com reported 2025-04-29 that An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. For all patients, trough levels over time were used to calculate the patient’s mean exposure to AFM24. Patients were then split into high and low AFM24 exposure groups for the analysis using the respective median as a cut-off. aAdsList.push(‘Article’); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Key Findings from the Exposure-Response AnalysisObjective Response Rate (ORR): 33.3% in the high-exposure group vs. 5.6% in the low-exposure group (p=0.0059)Disease Control Rate (DCR): 83.3% vs. 58.3% (p=0.0367)Median Progression-Free Survival (mPFS): 7.33 vs. 2.86 monthsOverall Survival (OS): Not yet mature in the high-exposure group vs. 13 months in the low-exposure group A quartile analysis further confirmed the exposure-efficacy relationship, showing a stepwise increase in ORR from 0% in the lowest quartile to 50% in the highest. Subgroup analysis of 55 patients treated with AFM24 plus atezolizumab showed consistent results: 37.04% ORR in the high-exposure group vs. 7.14% in the low group. Importantly, higher exposure was not associated with an increased rate of more serious or severe adverse events. “Advanced NSCLC is a devastating disease and remains an area of high unmet need,” said Andreas Harstrick, MD, Chief Medical Officer of Affimed. “These findings strengthen our clinical rationale for dose optimization and highlight the potential of AFM24 – particularly in combination with atezolizumab – as a novel, chemotherapy-free, immunotherapy-based treatment approach. Importantly, the data suggest that achieving higher drug exposure early in treatment may prevent rapid disease progression.”Further Development Pharmacokinetic (PK) modeling indicates that a 720 mg weekly dose of AFM24—previously established as safe—achieves target exposure levels by the second week of treatment that correspond to the high exposure group in the post-hoc analysis. Based on these findings, Affimed will include the 720 mg dose moving forward to optimize clinical benefit and reduce early progression risk. “These data provide compelling evidence that higher exposure may translate to better outcomes in patients with advanced NSCLC,” Dr. Harstrick added. “With dose optimization in hand, we are positioned to advance AFM24 in its potential to deliver durable benefit in a difficult-to-treat patient population.”Conclusions The data show a strong correlation between exposure and clinical outcome with a significantly increased risk for early tumor progression in the low exposure group. PK modeling suggests that a dose of 720 mg AFM24 weekly will result in exposure levels exceeding the cutoff for the high exposure group as early as week two. The 720 mg dose, which has already been established as safe in the phase 1 trial, will be used in future AFM24 studies. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.About AFM24 AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK® platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com. Investor Relations Contact Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102Media ContactMary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: m.sandin@affimed.com Source: Affimed N.V.2025 GlobeNewswire, Inc., source Press Releases
Is It Worth Investing in Affimed N.V (NASDAQ: AFMD) Right Now?
Company’s 36-month beta value is 2.07.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AFMD is 13.02M, and currently, short sellers hold a 5.29% ratio of that floaft. The average trading volume of AFMD on May 02, 2025 was 99.16K shares.
AFMD’s Market Performance
AFMD’s stock has seen a 23.60% increase for the week, with a 54.95% rise in the past month and a 12.31% gain in the past quarter. The volatility ratio for the week is 10.22%, and the volatility levels for the past 30 days are at 12.04% for Affimed N.V The simple moving average for the past 20 days is 43.99% for AFMD’s stock, with a -54.92% simple moving average for the past 200 days.
Analysts’ Opinion of AFMD
Many brokerage firms have already submitted their reports for AFMD stocks, with H.C. Wainwright repeating the rating for AFMD by listing it as a “Buy.” The predicted price for AFMD in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 12, 2022 of the previous year 2022.
Stifel, on the other hand, stated in their research note that they expect to see AFMD reach a price target of $2, previously predicting the price at $9. The rating they have provided for AFMD stocks is “Hold” according to the report published on October 10th, 2022.
AFMD Trading at 28.74% from the 50-Day Moving Average
After a stumble in the market that brought AFMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.71% of loss for the given period.
Volatility was left at 12.04%, however, over the last 30 days, the volatility rate increased by 10.22%, as shares surge +54.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.77% upper at present.
During the last 5 trading sessions, AFMD rose by +23.60%, which changed the moving average for the period of 200-days by -78.43% in comparison to the 20-day moving average, which settled at $0.7641. In addition, Affimed N.V saw -7.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AFMD
Current profitability levels for the company are sitting at:
- -80.05 for the present operating margin
- 1.0 for the gross margin
The net margin for Affimed N.V stands at -79.78. The total capital return value is set at -3.03. Equity return is now at value -151.46, with -88.07 for asset returns.
Based on Affimed N.V (AFMD), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at -5.97. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is -51.7.
Currently, EBITDA for the company is -102.38 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 23.15. The receivables turnover for the company is 0.19for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In a nutshell, Affimed N.V (AFMD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
